TherapeuticsMD (TXMD) Misses Q4 EPS by 1c

TherapeuticsMD (NASDAQ: TXMD) reported Q4 EPS of ($0.10), $0.01 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $4.1 million versus the consensus estimate of $4.66 million.

For earnings history and earnings-related data on TherapeuticsMD (TXMD) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Vera Bradley (VRA) Misses Q1 EPS by 26c ; Offers Guidance
• The Lovesac Company (LOVE) Tops Q1 EPS by 29c